Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.
Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…Efficacy of perampanel in paroxysmal kinesigenic dyskinesia
Objective: To explore the efficacy and safety of perampanel in the treatment of paroxysmal kinesigenic dyskinesia (PKD) Background: Perampanel is a new type of antiepileptic…Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…A Retrospective Review of Amantadine in Progressive Supranuclear Palsy
Objective: To determine the efficacy and tolerability of amantadine in Progressive supranuclear palsy (PSP). Background: PSP is one of the most common atypical parkinsonian disorders,…Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson’s Disease Based on Network Pharmacology and Molecular Docking
Objective: Based on the method of network pharmacology, this paper discusses the potential effects and mechanisms of SGD in the treatment of pain in PD. Background:…Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset
Objective: To determine the pharmacokinetic (PK) profile of L-3,4-dihydroxyphenylalanine (L-DOPA) in the common marmoset (Callithrix jacchus). Background: The common marmoset has been used to model…Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials
Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study
Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach
Objective: To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in…Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.
Objective: Investigation on Parkinson's patients with therapy-resistant tremor usingapomorphine-pen injection for alleviation of resting tremor. Background: In Parkinson’s disease one of the major disturbing symptoms…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 34
- Next Page »